Cleerly LABS vs Us2.v1
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
These tools are adjacent rather than direct competitors, as they serve different diagnostic needs within cardiology. Cleerly LABS specializes in AI-powered analysis of coronary CT angiography (CCTA) to assess coronary artery disease, while Us2.v1 provides fully automated AI analysis for echocardiography, focusing on a broader range of cardiac measurements and disease detection. The choice between them depends entirely on the specific cardiac imaging modality being utilized for patient evaluation.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Cleerly LABS is designed for comprehensive analysis of coronary CT angiography (CCTA) images. In contrast, Us2.v1 provides fully automated AI analysis specifically for echocardiography.
Cleerly LABS aids in detecting, quantifying, and characterizing atherosclerosis and stenosis from CCTA, supporting personalized heart disease risk assessment and tracking progression. Us2.v1 offers automated echocardiography analysis for measurements, general disease detection, and specific conditions like cardiac amyloidosis and pulmonary hypertension, comparing findings to international reference guidelines.
Cleerly LABS explicitly states integration capabilities with PACS, RIS, and EHR systems via its Cleerly Proxy. While Us2.v1 generates comprehensive structured reports, its provided description does not specify direct integration with PACS, RIS, or EHR systems.
Cleerly LABS provides comprehensive coronary plaque assessment (volume, type), stenosis detection and quantification, 3D visualization, and personalized heart disease risk assessment. Us2.v1 generates comprehensive structured reports with measurements, disease detection, and findings, featuring editable annotations, conclusions, and comparison to international reference guidelines.
Cleerly LABS explicitly lists 'Tracking disease progression over time' as a key feature, aiding in longitudinal patient management. Us2.v1's description focuses on real-time analysis and reporting of current echocardiography findings, without mentioning features for tracking disease progression.
More Comparisons
Backers
Who funded each tool's parent company.